{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T23:13:45Z","timestamp":1779923625201,"version":"3.53.1"},"reference-count":29,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2013,7,16]],"date-time":"2013-07-16T00:00:00Z","timestamp":1373932800000},"content-version":"vor","delay-in-days":106,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1016\/j.jhep.2012.10.027","type":"journal-article","created":{"date-parts":[[2012,11,5]],"date-time":"2012-11-05T17:51:43Z","timestamp":1352137903000},"page":"792-800","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":98,"title":["Clinical management of drug\u2013drug interactions in HCV therapy: Challenges and solutions"],"prefix":"10.1016","volume":"58","author":[{"given":"David","family":"Burger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Back","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Buggisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Buti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Crax\u00ed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham","family":"Foster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartwig","family":"Klinker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Larrey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Nikitin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanislas","family":"Pol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Puoti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Romero-G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heiner","family":"Wedemeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Zeuzem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2012.10.027_b0005","first-page":"344","article-title":"Fatal lactic acidosis and pancreatitis associated with ribavirin and didanosine therapy","volume":"13","author":"Butt","year":"2003","journal-title":"AIDS Read"},{"key":"10.1016\/j.jhep.2012.10.027_b0010","doi-asserted-by":"crossref","unstructured":"Poordad F, Lawitz E, Gordon S, Bourli\u00e8re M, Vierling J, Poynard T, et al. Concomitant medication use in patients with hepatitis C genotype 1 treated with boceprevir combination therapy. In: Sixty second annual meeting of the American Association for the Study of Liver Diseases, San Francisco, California, November 4\u20138, 2011 [poster 937].","DOI":"10.1016\/S0168-8278(11)60014-7"},{"key":"10.1016\/j.jhep.2012.10.027_b0015","unstructured":"EMA. Incivo; Summary of product characteristics. 2012 [cited 2012]; Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002313\/WC500115529.pdf."},{"key":"10.1016\/j.jhep.2012.10.027_b0020","unstructured":"EMA. Victrelis; Summary of product characteristics. 2012 [cited 2012]; Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002332\/WC500109786.pdf."},{"key":"10.1016\/j.jhep.2012.10.027_b0025","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1124\/dmd.110.036996","article-title":"Characterization of human liver enzymes involved in the biotransformation of boceprevir, a hepatitis C virus protease inhibitor","volume":"39","author":"Ghosal","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.jhep.2012.10.027_b0030","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1053\/j.gastro.2006.02.034","article-title":"Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics","volume":"130","author":"Ho","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2012.10.027_b0035","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1053\/j.gastro.2006.07.013","article-title":"Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study","volume":"131","author":"Reesink","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2012.10.027_b0040","unstructured":"Stone J, Wenning L, Hang Y, Su J, Gupta S, Tsai K, et al. Assessment of boceprevir pharmacokinetic\/pharmacodynamic relationships for sustained viral response and occurrence of anemia from phase 3 data. In: 62nd Annual meeting of the American association for the study of liver diseases, San Francisco, California, November 4\u20138, 2011 [poster 1342]."},{"key":"10.1016\/j.jhep.2012.10.027_b0045","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1093\/jac\/dkn421","article-title":"Usefulness of monitoring ribavirin plasma concentrations to improve treatment response in patients with chronic hepatitis C","volume":"62","author":"Morello","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jhep.2012.10.027_b0050","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/hep.24470","article-title":"Telaprevir, boceprevir, cytochrome P450 and immunosuppressive agents-a potentially lethal cocktail","volume":"54","author":"Charlton","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2012.10.027_b0055","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/hep.24443","article-title":"Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus","volume":"54","author":"Garg","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2012.10.027_b0060","unstructured":"Hulskotte E, Gupta S, Xuan Y, Zutven van M, O\u2019Mara E, Galitz L, et al. Pharmacokinetic interaction between the HCV protease inhibitor boceprevir and the calcineurin inhibitors cyclosporine and tracolimus. In: Sixteenth annual meeting of HEP DART, Koloa, Hawaii, December 4\u20138, 2011 [poster 123]."},{"key":"10.1016\/j.jhep.2012.10.027_b0065","doi-asserted-by":"crossref","unstructured":"Coilly A, Roche B, Botta-Fridlund D, Leroy V, Pageaux P, Si-Ahmed S, et al. Efficacy and safety of protease inhibitors for severe hepatitis c recurrence after liver transplantation: a first multicentric experience. In: Fortyseventh annual meeting of the European association for the study of the liver, April 18\u201322, 2012 [oral presentation 47].","DOI":"10.1016\/S0168-8278(12)60061-0"},{"key":"10.1016\/j.jhep.2012.10.027_b0070","unstructured":"Boyd S, Hadigan C, Pau A, Kovacs J, Alfaro R, Chairez C, et al. Darunavir\/ritonavir does not significantly increase plasma concentrations of orally inhaled beclomethasone in healthy volunteers. In: Nineteenth conference on retroviruses and opportunistic infections (CROI), March 5\u20138 2012, Seattle [poster 611]."},{"key":"10.1016\/j.jhep.2012.10.027_b0075","unstructured":"Garg V, Chandorkar G, Yang Y, Adda N, McNair L, Alves K, et al. The effect of CYP3A inhibitors and inducers on the pharmacokinetics of telaprevir. In: Sixth international workshop on clinical pharmacology of hepatitis therapy, Cambridge, MA, June 22\u201323, 2011 [abstract PK_13]."},{"key":"10.1016\/j.jhep.2012.10.027_b0080","unstructured":"Kassera C, Hughes E, Treitel M, Gupta S, O\u2019Mara E. Clinical pharmacology of BOC: metabolism, excretion and drug\u2013drug interactions. In: Eighteenth conference on retroviruses and opportunistic infections, Boston, Massachusetts, Ferbruary 27\u2013March 2, 2011 [abstract 118]."},{"key":"10.1016\/j.jhep.2012.10.027_b0085","unstructured":"Heeswijk van R, Vandevoorde A, Verboven P, Boogaerts G, De Paepe E, Solingen-Ristea van R, et al. The pharmacokinetic interaction between methadone and the investigational HCV protease inhibitor telaprevir. 46th Annual meeting of the European association for the study of the liver (The International Liver Congress\u2122 2011), Berlin, Germany, March 30\u2013April 3, 2011 [poster 1244]."},{"key":"10.1016\/j.jhep.2012.10.027_b0090","unstructured":"Hulskotte EGJ, Feng HP, Bruce RD, Webster LR, Xuan F, Lin WH, et al. Pharmacokinetic interaction between HCV protease inhibitor boceprevir and methadone or buprenorphine in subjects on stable maintenance therapy. In: Seventh international workshop on clinical pharmacology of hepatitis therapy, Cambridge, MS, USA, June 27\u201328, 2012 [abstract PK_09]."},{"key":"10.1016\/j.jhep.2012.10.027_b0095","unstructured":"Luo X, Trevejo J, Heeswijk van R, Garg V. No significant effect of the HCV protease inhibitor telaprevir on pharmacokinetics and pharmacodynamics of buprenorphine in HCv-negative volunteers. In: Sixteenth annual meeting of HEP DART, Koloa, Hawaii, December 4\u20138, 2011 [poster 132]."},{"key":"10.1016\/j.jhep.2012.10.027_b0100","unstructured":"Heeswijk van R, Boogaerts G, Paepe de E, Solingen-Ristea van R, Garg V, Beumont M. The pharmacokinetic interaction between escitalopram and the investigational HCV protease inhibitor telaprevir. In: Fifth international workshop on clinical pharmacology of hepatitis therapy, June 23\u201324, 2010 [abstract 12]."},{"key":"10.1016\/j.jhep.2012.10.027_b0105","unstructured":"Hulskotte E, Gupta S, Xuan Y, Zutven van M, O\u2019Mara E, Galitz L, et al. Coadministration of the HCV protease inhibitor boceprevir has no clinically meaningful effect on the pharmacokinetics of the selective serotonin reuptake inhibitor escitalopram in healthy volunteers. In: Sixteenth annual meeting of HEP DART, Koloa, Hawaii, December 4\u20138, 2011 [poster 121]."},{"key":"10.1016\/j.jhep.2012.10.027_b0110","unstructured":"Garg V, Chandorkar G, Smith F, Alves K, Heeswijk van R. The effect of telaprevir on the pharmacokinetics of midazolam and digoxin. In: Sixth international workshop on clinical pharmacology of hepatitis therapy, Cambridge, MA, June 22\u201323, 2011 [abstract PK_12]."},{"key":"10.1016\/j.jhep.2012.10.027_b0115","unstructured":"Luo X, Van Heeswijk R, Alves K, Garg V. The effect of telaprevir on the pharmacokinetics of alprazolam and zolpidem in healthy volunteers. In: Sixth international workshop on clinical pharmacology of hepatitis therapy, Cambridge, MA, June 22\u201323, 2011 [abstract PK_11]."},{"key":"10.1016\/j.jhep.2012.10.027_b0120","doi-asserted-by":"crossref","first-page":"4569","DOI":"10.1128\/AAC.00653-11","article-title":"Effect of the hepatitis C virus protease inhibitor telaprevir on the pharmacokinetics of amlodipine and atorvastatin","volume":"55","author":"Lee","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhep.2012.10.027_b0125","unstructured":"Hulskotte E, Gupta S, Xuan Y, Zutven van M, O\u2019Mara E, Galitz L, et al. Pharmacokinetic evaluation of the interaction between the HCV protease inhibitor boceprevir and the HMG-CoA reductase inhibitors atorvastatin and pravastatin. In: Sixteenth annual meeting of HEP DART, Koloa, Hawaii, December 4\u20138, 2011 [poster 122]."},{"key":"10.1016\/j.jhep.2012.10.027_b0130","unstructured":"Chu X, Cai X, Cui D, Evers R, Green M, Ghosal A, et al. In vitro assessment of drug\u2013drug interaction potential of boceprevir as an inhibitor and inducer of drug metabolizing enzymes and transporters. In: Sixty second annual meeting of the American Association for the Study of Liver Diseases, San Francisco, California, November 4\u20138, 2011 [poster 378]."},{"key":"10.1016\/j.jhep.2012.10.027_b0135","unstructured":"Jumes P, Feng HP, Xuan F, Youngberg S, Wagner J, Butterton J. Pharmacokinetic interaction between the HCV protease inhibitor boceprevir and digoxin in healthy adult volunteers. In: Seventh international workshop on clinical pharmacology of hepatitis therapy, Cambridge, MS, USA, June 27\u201328, 2012 [abstract PK_05]."},{"key":"10.1016\/j.jhep.2012.10.027_b0140","unstructured":"Garg V, Yang Y, Smith F, Adda N, Van Heeswijk R. The pharmacokinetic interaction between an oral contraceptive containing ethinyl estradiol and norethindrone and telaprevir. In: Sixth international workshop on clinical pharmacology of hepatitis therapy, Cambridge, MA, June 22\u201323, 2011 [abstract PK_17]."},{"key":"10.1016\/j.jhep.2012.10.027_b0145","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.clpt.2004.09.008","article-title":"Peginterferon alfa-2a does not alter the pharmacokinetics of methadone in patients with chronic hepatitis C undergoing methadone maintenance therapy","volume":"77","author":"Sulkowski","year":"2005","journal-title":"Clin Pharmacol Ther"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827812008288?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827812008288?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:32:18Z","timestamp":1759174338000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827812008288"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["S0168827812008288"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2012.10.027","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2013,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical management of drug\u2013drug interactions in HCV therapy: Challenges and solutions","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2012.10.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 European Association for the Study of the Liver. Published by Elsevier Ireland Ltd.","name":"copyright","label":"Copyright"}]}}